Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Pembrolizumab in Stage IV NSCLC with Bone Metastases
NCT03996473Phase 1Terminated
- Sponsor
- Bayer
- Start
- Mar 2020
- Primary completion
- Apr 2021
- Modality
- Radiopharmaceutical
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of radium-223 dichloride in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bayer. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events in Phase 1 up to 218 days, Number of Participants With Treatment-emergent Serious Adverse Events in Phase 1 up to 278 days and 2 more. Started Mar 2020; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03996473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996473.